Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-08653945 Bioavailability Across Injection Sites in Overweight/Obese Adults
NCT07725809Phase 1Active, not recruiting
- Sponsor
- Pfizer
- Start
- Jul 2026
- Primary completion
- Jan 2027
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of PF-08653945 in obesity and Overweight (4 cohorts), sponsored by Pfizer. Primary endpoints: Area Under the Curve up to 57 days and Maximum Observed Concentration up to 57 days. Started Jul 2026; status: active, not recruiting.
02
Drugs
PF-08653945
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT07725809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07725809.